ipilimumab,nivolumab,durvalumab,paclitaxel,vinorelbine,carboplatin,cisplatin,gemcitabine,docetaxel,pemetrexed
bms,astrazeneca
['nadim2', 'aegean', 'cm816']
 aegean focus on path-response #aacr23 pcr: 17.2% vs 4.3% ( 13%) mpr: 33.3% vs 12.3% ( 21%)
...consistent across predefined subgroups! pcr in cm816 24 vs 2.2% ( 21.8%); nadim2 36.8 vs 6.9% ( 29.9%)
pcr remains t key factor in neoadj setting to integrate w/ ctdna 
MD PhD, lung oncologist & researcher @IEOufficiale; @myESMO Communication Committee Chair; #LungCancer Molecular target-believer #LCSM